Browsing Centre for Preventative Neurology by Title
Now showing items 26-45 of 144
-
Demyelinating Events Following Initiation of Anti-TNFα Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis.
(2021-04-16)OBJECTIVE: To establish the incidence of demyelination in patients who have received anti-tumor necrosis factor alpha (anti-TNFα) therapy, through analysis of adverse events reported in a prospective cohort of patients ... -
Differences in the Presentation and Progression of Parkinson's Disease by Sex
(Wiley, 2020-10-01) -
Differing Impact of DMT on Relapse and Progression: Time to Consider Inflammation and Neuroprotection Separately?
The artificial distinction between relapsing remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS) can lead to substantial difficulties in decisions on disease-modifying therapy (DMT) at ... -
Digesting science: Developing educational activities about multiple sclerosis, prevention and treatment to increase the confidence of affected families.
(2020-11-13)BACKGROUND: The majority of information sources for children of people with multiple sclerosis (MS) are paper, or text, based and require high levels of literacy. OBJECTIVE: To develop educational activities to inform ... -
Domotics, smart homes and Parkinson’s disease
(IOS Press, 2021-02-19) -
Early detection of dementia with default-mode network effective connectivity
(Springer Nature, 2024-06-06)Altered functional connectivity precedes structural brain changes and symptoms in dementia. Alzheimer’s disease is the largest contributor to dementia at the population level, and disrupts functional connectivity in the ... -
Eligibility for antiamyloid treatment: preparing for disease-modifying therapies for Alzheimer's disease.
(BMJ Publishing Group, 2024-06-11)BACKGROUND: Disease-modifying therapies (DMTs) for Alzheimer's disease (AD) have early evidence of efficacy. Widespread delivery of DMTs will require major service reconfiguration. Treatment pathways will need to include ... -
Embedding Patient Input in Outcome Measures for Long-Term Disease-Modifying Parkinson Disease Trials.
(2023-12-22)BACKGROUND: Clinical trials of disease-modifying therapies in PD require valid and responsive primary outcome measures that are relevant to patients. OBJECTIVES: The objective is to select a patient-centered primary outcome ... -
Experiences of Living With the Nonmotor Symptoms of Parkinson's Disease: A Photovoice Study
(Wiley, 2024-06)<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Nonmotor symptoms (NMSs) are frequently experienced by people with Parkinson's disease (PD) and are often perceived as their most ...